Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cue Biopharma Inc (NQ: CUE )

1.130 +0.110 (+10.78%)
Streaming Delayed Price Updated: 11:41 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cue Biopharma Inc

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Via Benzinga
Where Cue Biopharma Stands With Analysts
Via Benzinga
Cue Biopharma Earnings Perspective: Return On Capital Employed
Via Benzinga
Cue Biopharma's Earnings Outlook
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Medical Moonshots: 3 Biotech Stocks Set to Skyrocket
Though risky, investors who buy biotech stocks watch their portfolios skyrocket when their drugs work as intended. 
Via InvestorPlace
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023
CUE stock results show that Cue Biopharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023
CUE stock results show that Cue Biopharma beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
Via InvestorPlace
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24... 
Via Benzinga
The Truth About IPO Investing
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Biotech Stocks to Buy as Companies Ink Major Deals
Pharmaceutical and biotech companies will soon face generic competition, creating big opportunity for these top biotech stocks to buy. 
Via InvestorPlace
3 Biotech Stocks Sitting on Huge-Upside Catalysts
The biotech boom is hot. According to Grand View, it could be worth $2.44 trillion. It's why we have an eye on these top biotech stocks. 
Via InvestorPlace
7 Hot Growth Stocks Poised to Triple in 2023
These hot growth stocks to buy can triple in price in 2023, with some holding impressive upside that's much higher. 
Via InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Here are seven hot ones to consider. 
Via InvestorPlace
Earnings Scheduled For March 21, 2023
Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS